rs5186 — AGTR1 A1166C
Risk factor / Drug response · ~30% global (C allele)
rs5186 in the angiotensin II type 1 receptor (AGTR1) is associated with essential hypertension, aortic stiffness, and differential response to ACE inhibitors and ARBs. The C allele increases receptor sensitivity to angiotensin II.
Molecular Mechanism
The A1166C variant in the 3' UTR affects microRNA-155 binding, increasing AGTR1 mRNA stability and receptor expression. Higher AT1 receptor density amplifies the vasoconstrictive and aldosterone-stimulating effects of angiotensin II.
Peptide Therapeutic Relevance
Angiotensin-targeting peptides and AT1 receptor antagonist peptides are established therapeutic classes. PepFold generates novel candidates combining genetic target data with 3D structural prediction for receptor-specific binding.
Condition: Hypertension (Essential)
Essential hypertension affects 1.3 billion adults worldwide. AGT (rs699) and AGTR1 (rs5186) variants modulate the renin-angiotensin-aldosterone system (RAAS), the primary pharmacological target for blood pressure control.
Prevalence: 1.3 billion adults worldwide (~30% of adult population)
Related Variants
Analyze rs5186 with PepFold
Submit rs5186 and get ranked peptide candidates with 3D structures and synthesis protocols in under 2 minutes.